1st Quarter 2026 Results

1st Quarter 2026 Sales

$24.1B

Worldwide increased ▲ **9.9%**

Excluding the impact of translational currency

Stelara impacted results by ~(540) basis points

Worldwide increased ▲ **6.4%**[1]

Diluted earnings per share (EPS) **$2.14**

Adjusted diluted earnings per share[1]

$2.70

Worldwide decreased ▼ **(2.5)%**



Joaquin Duato
Chairman & Chief Executive Officer
Johnson & Johnson

“Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact. The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the potential to transform patient outcomes and create sustainable, long-term value for shareholders.”

$15.4 billion

Worldwide Innovative Medicine sales

Innovative Medicine worldwide reported sales increased 11.2% or 7.4% operationally[2]. Stelara impacted results[2] by ~(920) basis points. Primary operational drivers:

- Tremfya (guselkumab)
- DARZALEX (daratumumab)
- CAPLYTA (lumateperone) capsules
- CARVYKTI (ciltacabtagene autoleucel)
- Spravato (esketamine) nasal spray
- Erleada (apalutamide)
- RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib)
- INVEGA SUSTENNA paliperidone palmitate

$8.6 billion

Worldwide MedTech sales

MedTech worldwide reported sales increased 7.7% or 4.6% operationally[2] Primary operational drivers:

- Electrophysiology
- Abiomed
- Shockwave
- Trauma
- Wound Closure & Healing
- Contact Lenses
- Biosurgery
- Surgical Vision

Johnson&Johnson

For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson's earnings release issued on April 14, 2026 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx

[1] Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[2] Non-GAAP measure; excludes the impact of translational currency.

Note: Values may be rounded